Weight loss medications have transformed obesity treatment, but access to a prescription may be only one part of the picture. Researchers from University College London and the University of Cambridge argue that patients also need realistic access to nutritious food, dietary guidance and ongoing medical support.
Their article, published in Nature Medicine, is a correspondence, not a new clinical trial. It does not show that weight loss drugs cause health inequalities or that people with limited access to healthy food will necessarily have worse results. Instead, the researchers are raising a concern: As medications such as semaglutide and tirzepatide become more widely used, some patients may have more resources than others to manage the nutritional changes that can come with eating less.
One of the authors, Dr. Adrian Brown of University College London, has received researcher-led grants from Novo Nordisk. He has also reported honoraria from Novo Nordisk, Eli Lilly and several nutrition and health companies outside the submitted work. Novo Nordisk and Eli Lilly manufacture medications used for weight management and diabetes. The authors did not receive funding for this correspondence.
“The key question is not simply who can access these medications, but who can benefit from them in the long term,” said lead author Dr. Marie Spreckley of the University of Cambridge.
Semaglutide, sold under brand names including Wegovy and Ozempic, and tirzepatide, sold as Mounjaro, are incretin-based medications. They can reduce appetite and help people feel full sooner. Some patients also experience gastrointestinal side effects such as nausea.
Those effects can support weight loss, but they can also make it more important to pay attention to what someone is eating. When appetite drops, a person may have fewer opportunities to get enough protein, fiber, vitamins and minerals. The researchers warn that some patients could be at risk of poor diet quality, inadequate nutrient intake or loss of lean body mass, which includes muscle, without appropriate guidance and monitoring.
The article focuses on the United Kingdom, where the researchers say food insecurity affects 12% of households. The authors are concerned that patients with fewer financial resources may have a harder time affording nutrient-dense foods or accessing nutrition counseling and ongoing health care.
That concern has relevance beyond the United Kingdom. Food prices, access to health care and insurance coverage also shape eating habits and medical care in the United States. General advice to eat a balanced diet may not be enough if patients cannot afford recommended foods, do not know how to adjust their meals as appetite changes or are struggling with side effects.
“Guidance that assumes everyone can afford and access healthy food risks being unrealistic and inequitable,” said co-author Dr. Cara Ruggiero of the University of Cambridge.
The researchers are not arguing against weight loss medications. They note that large clinical trials have shown that incretin-based therapies can lead to substantial, sustained weight loss and improvements in metabolic health. Their point is that medication alone may not address every factor that affects long-term health.
The correspondence also highlights a broader issue in nutrition advice: Recommendations need to work in real life. A patient who is eating much less may need practical guidance on building meals around nutrient-dense foods, preserving muscle and managing nausea or early fullness. That support may look different depending on a person’s health needs, budget and access to care.
The researchers argue that access to dietary support should be considered alongside access to medication as these treatments become more common.
“The key message is clear: these treatments are powerful, but their long-term public health impact will depend on whether the right support systems are in place to ensure equitable and safe access for all patients,” Brown said.